KYUNG NAM PHARM.CO.,LTD. Logo

KYUNG NAM PHARM.CO.,LTD.

South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.

053950 | KO

Overview

Corporate Details

ISIN(s):
KR7053950002
LEI:
Country:
South Korea
Address:
경상남도 의령군 동동리 1539-5, 의령군
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 1957, Kyung Nam Pharm Co., Ltd. is a South Korean pharmaceutical company specializing in the manufacturing and sale of over-the-counter (OTC) medicines, health functional foods, and cosmetics. The company is renowned for its flagship brand, Lemona, which was introduced in 1983 as the country's first powdered Vitamin C and has since become a leading product in the vitamin and inner-beauty markets. Its portfolio also includes well-known OTC products such as 'PM' for athlete's foot and 'Minol F Troche' for sore throats. Kyung Nam Pharm is also a prominent manufacturer of human placenta-based medicines, reinforcing its long-standing focus on consumer health and wellness.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
Share Issue/Capital Change
전환가액의조정
Korean 22.8 KB
2025-08-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 87.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-08-11 00:00
Share Issue/Capital Change
전환가액의조정
Korean 22.0 KB
2025-07-10 00:00
Share Issue/Capital Change
전환가액의조정
Korean 21.6 KB
2025-06-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.1 KB
2025-06-23 00:00
Share Issue/Capital Change
전환가액의조정
Korean 14.4 KB
2025-06-10 00:00
Share Issue/Capital Change
전환가액의조정
Korean 21.1 KB
2025-05-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 87.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.5 MB
2025-05-12 00:00
Share Issue/Capital Change
전환가액의조정
Korean 20.7 KB
2025-04-10 00:00
Share Issue/Capital Change
전환가액의조정
Korean 20.7 KB
2025-03-20 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 18.9 KB
2025-03-12 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 581.0 KB
2025-03-10 00:00
Share Issue/Capital Change
전환가액의조정
Korean 20.3 KB

Automate Your Workflow. Get a real-time feed of all KYUNG NAM PHARM.CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KYUNG NAM PHARM.CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KYUNG NAM PHARM.CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea
182400
NLS Pharmaceutics Ltd. Logo
Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.
United States of America
NLSP
NovaBay Pharmaceuticals, Inc. Logo
Develops clinically-proven anti-infective therapies for eyecare, skincare, and wound care.
United States of America
NBY
Novacyt Logo
Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.
France
ALNOV
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland
NOVN
NOVAVAX INC Logo
Develops and commercializes nanoparticle vaccines for serious infectious diseases.
United States of America
NVAX
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea
229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark
NOVO
NRX Pharmaceuticals, Inc. Logo
Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.
United States of America
NRXP
NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA

Talk to a Data Expert

Have a question? We'll get back to you promptly.